Stanniocalcin Polypeptides for Ocular Inflammation and Retinal Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eye diseases such as retinal degenerations, diabetic retinopathy, and glaucoma are limited in effectiveness, with a need for more robust therapeutic strategies to prevent and treat these conditions, particularly in addressing inflammation and apoptosis.
Innovation Solution
Administration of polypeptides with anti-inflammatory or anti-apoptotic properties, such as stanniocalcin family members (STC-1 and STC-2) or Tumor Necrosis Factor-Inducible Gene 6 (TSG-6), either alone or expressed by genetically modified cells, to treat or prevent eye diseases through various delivery methods including intravitreal, subretinal, or systemic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for eye diseases, then current treatment standards are maintained, but therapeutic effectiveness remains limited
Solution Approach 1:
The patent changes the molecular parameters of therapy by using polypeptides with specific anti-inflammatory and anti-apoptotic properties (such as stanniocalcin family members and TSG-6) rather than conventional drugs. This parameter change in therapeutic mechanism enables treatment of eye diseases with limited current options, improving both effectiveness and adaptability.
Solution Approach 2:
The patent introduces polypeptide intermediaries that mediate between the disease pathology and therapeutic response. These polypeptides act as molecular messengers that reduce inflammation and prevent apoptosis, serving as intermediaries to restore eye tissue function where conventional therapies fail.
2Reliability
If inflammation and apoptosis are addressed in eye disease therapy, then disease progression is reduced, but treatment complexity increases
Solution Approach 1:
The patent segments the therapeutic function into distinct polypeptide components, each targeting specific pathways (anti-inflammatory vs. anti-apoptotic). This segmentation allows independent optimization of each function while simplifying the overall treatment strategy by focusing on specific molecular mechanisms rather than complex multi-drug regimens.
Solution Approach 2:
The patent uses genetically modified cells that copy and express therapeutic polypeptides (such as stanniocalcin family members) to deliver treatment effects. This copying approach simplifies therapy delivery by using cell-based systems that can be manufactured and administered as whole cells rather than complex molecular formulations.
3Reliability
If polypeptides are administered to treat eye diseases, then healing is promoted and vision is preserved, but delivery challenges arise
Solution Approach 1:
The patent develops polypeptide-based therapies that can be delivered through multiple routes (intravitreal, subretinal, or systemic administration), making the treatment universally applicable to different disease stages and patient needs. This multi-functionality in delivery approaches simplifies clinical operation by providing flexibility rather than requiring complex specialized procedures.
Data Source
AI summary
The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.